BP-008

BP-008 is a pediatric extended-release (ER) formulation developed by Brillian Pharma as part of its proprietary 'Unidose' product line. The Unidose platform focuses on reformulating existing therapeutic agents into child-friendly, single-dose formats to improve dosing precision and patient adherence in pediatric populations. BP-008 is specifically designed as an oral suspension or a lyophilized powder intended for reconstitution, providing a controlled-release profile. While the specific active pharmaceutical ingredient (API) and its primary therapeutic indication have not been publicly disclosed by the developer, the product is categorized within Brillian Pharma's extended-release formulation technology pipeline.